ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

FAB Fusion Antibodies Plc

3.45
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Fusion Antibodies Plc LSE:FAB London Ordinary Share GB00BDQZGK16 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.45 3.30 3.60 3.45 3.45 3.45 25,672 08:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 2.9M -2.6M -0.0272 -1.27 3.29M
Fusion Antibodies Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker FAB. The last closing price for Fusion Antibodies was 3.45p. Over the last year, Fusion Antibodies shares have traded in a share price range of 3.10p to 9.875p.

Fusion Antibodies currently has 95,365,564 shares in issue. The market capitalisation of Fusion Antibodies is £3.29 million. Fusion Antibodies has a price to earnings ratio (PE ratio) of -1.27.

Fusion Antibodies Share Discussion Threads

Showing 3901 to 3923 of 4100 messages
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older
DateSubjectAuthorDiscuss
17/1/2024
11:13
These last couple of broker notes give a good explanation of the technology which is world first. Definitely some challenges though and next trading update will be critical in determining need to raise funds again.

hxxps://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2023/02/20230215-Fusion-Antibodies-plc-FAB.L-Allenby-Capital-OptiMAL-update.pdf?c3480=on

hxxps://wp-allenby-2020.s3.eu-west-2.amazonaws.com/media/2023/12/20231213-Fusion-Antibodies-plc-FAB.L-Allenby-Capital-Update.pdf?c3963=on

gtc1508
17/1/2024
11:02
What's the investment case here? Tiny market cap of £3m, losing money, possibly running low on cash, no particular IP or moat? Just looking for a home for some money, the chart looks interesting but the financials seem poor, from my quick initial look anyway.
cyberbub
17/1/2024
10:33
The video I deleted is referenced in that presentation below and on their website
gtc1508
17/1/2024
10:01
No it was just a guess at why he deleted the post.
luckyabbeygale
17/1/2024
09:40
CEO PRESENTATION

hxxps://youtu.be/IAvbf90GgvQ?feature=shared

gtc1508
15/1/2024
13:57
I posted a video from there website, the link to which was circulating on twitter. Someone messaged me and said they had been asked to remove it so I also did this.
gtc1508
15/1/2024
13:49
Soo lucky have you added since reading his post?
billthebank
15/1/2024
13:28
and another 200K at 12.26.

I feel this rise may end up going a lot higher than the last big rise we had.

luckyabbeygale
15/1/2024
13:23
I have just dicovered a very big buy of 173K at 12.15.

When other people see this the buying is going to go ballistic.

luckyabbeygale
15/1/2024
12:21
Looks like gtc1508 posted inside information and then deleted it.
luckyabbeygale
15/1/2024
12:17
looking great!, a bit leaky i wonder?
lawson27
15/1/2024
12:01
This stock has multi bagger potential in the short term, I am surprised it dropped back so quickly after the NCI announcement
cbeadle
15/1/2024
11:43
Lowest ASK on show is now 5.5p, which is being paid.

f

fillipe
14/1/2024
18:48
Those sellers on Thursday was like idiots taking 5p a share. Since then they have all been bought back and more.
luckyabbeygale
14/1/2024
17:15
Sounded very good with results within the next 6/12
mcbull
14/1/2024
16:54
Who's this
leeawill20
11/1/2024
13:29
Looking good ??
bigjock36
11/1/2024
11:32
Wakey Wakey
bigjock36
11/1/2024
11:27
Oh hello, someones kicking the nest, cmon FAB
lawson27
10/1/2024
21:07
He is a real life Jack ass
bigjock36
10/1/2024
18:13
Yea, question is does management really have the expertise and clout to sell the brand to big investors-not penny punters. Should be an easy sell in reality-even getting the NCI in the US to show a remote interest in their antibody library is some feat one typically underappreciated by gormless UK II analysts who don't know their ars..from their elbows, and confirms the science side of things is worthwhile.
Persuading IIs that a single antibody with prospects (look at GSKs deal for early phase 2 respiratory AB they paid a billion + for the right to develop-ex China-which hasn't even been approved for clinical use yet to give one an idea of the scale and potential here. I'm afraid mgmt don't seem up to it, especially if they have to resort to Proactive to sell the story for funds.

cumnor
10/1/2024
15:06
Jak again?
daniel
09/1/2024
14:41
Absolutely!
jaknife
Chat Pages: 164  163  162  161  160  159  158  157  156  155  154  153  Older

Your Recent History

Delayed Upgrade Clock